2025 CLMC | Digital Technology Drives "Cardio-Diabetes Co-Management" Closed-Loop, Taking Lifestyle Intervention to the Next Level!
From October 25 to 26, 2025, the 5th China Healthy Lifestyle Medicine Conference (CLMC) was grandly held in Beijing. With the theme of "Building a Healthy Ecosystem for a Better Life", the conference gathered experts, scholars, industry elites and multi-field health advocates from across the country to discuss how to promote healthy lifestyles from medical intervention to the systematic construction of a social ecosystem.
The Survey on Chinese’s Heart showed that 52.9% of inpatients with coronary heart disease (CHD) in China have comorbid diabetes, and nearly 80% have abnormal glucose metabolism[1]. Whether in acute cardiovascular events or decompensation of chronic cardiovascular diseases, patients are prone to stress hyperglycemia or hypoglycemia, leading to acute fluctuations in blood glucose homeostasis, resulting in poorer cardiovascular outcomes. Previous studies have indicated that abnormal glucose metabolism or perioperative blood glucose fluctuations can significantly increase the risk of adverse prognosis in patients undergoing cardiovascular interventional or surgical treatment[2-8]. Although intensive management during the cardiovascular perioperative period improves short-term outcomes, continuous blood glucose control and glucose metabolism follow-up after discharge are still generally lacking. Systematic reviews and recent studies have pointed out that the evidence for long-term glucose metabolism management in patients with acute-phase or postoperative CHD is still weak[9]!
A New Paradigm of "Full-Cycle Digital Cardio-Diabetes Management": Sinocare Leads a New Path of Precision Management
Therefore, to address this practical gap, there is an urgent need to build a real-time, data-driven, full-cycle, personalized, and dynamic "cardio-diabetes co-management" system. By leveraging real-time data to drive healthy lifestyle management, this system integrates glucose metabolism and cardiovascular health into a unified framework, establishing a full closed-loop from hospitalization to post-discharge and from monitoring to intervention. This further empowers patients to achieve evidence-based lifestyle remodeling and long-term maintenance of metabolic homeostasis in real-life scenarios.
At the thematic session "Digital Intelligence Drives: Unlocking the Code of Cardio-Glucose Metabolic Health" during the conference, Sinocare Bio-Sensing Co., Ltd. (hereinafter referred to as "Sinocare") launched the innovative project "Full-Cycle Digital Management of Diabetes-Cardiovascular Diseases". 
Mr. Shaobo Li, chairman of Sinocare, delivered the opening speech at the CLMC
Diabetes and cardiovascular diseases, as common comorbidities, are characterized by traditional single and segmented management approaches, which fail to meet patients' long-term and comprehensive management needs.Leveraging the expertise of leading clinical specialists in cardiovascular diseases, combined with the technological advantages of continuous glucose monitoring (CGM), smart wearable devices, and digital health platforms, Sinocare is dedicated to establishing a management system that covers the entire disease course from 'screening-assessment-intervention-follow-up'.This will drive a strategic shift in chronic disease management from a 'treatment-centered' to a 'health-centered' approach.
This "innovation launch" focuses on 3 core sections for in-depth exploration and practice:
1.Building a closed-loop digital management system: Through the integration of CGM, wearable devices and cloud-based data platforms, synchronizing data of in-hospital and out-of-hospital patients to achieve intelligent risk warning.
2. Promoting the implementation of the "Four Modernizations" standards: In accordance with the framework of "Prescription-based Lifestyle, Medical Integration into Daily Life, Systematic Health Services, and Localization of Key Technologies" proposed by the Healthy Lifestyle Medicine Center of the National Cardiovascular Center, establish standard operating procedures (SOP) to provide replicable and scalable chronic disease management solutions for the industry.
3. Dual-drive of scientific research and clinical practice: Conduct large-scale real-world studies to evaluate the effectiveness of digital therapeutics in integrated heart and glucose management, and commit to promoting the formulation of relevant clinical guidelines and industry consensus.
From "One-Size-Fits-All" to "Personalized Precision": How Do Digital-Intelligent Technologies Reshape Cardio-Glucose Metabolic Health?
With the continuous increase in the number of patients with diabetes and cardiovascular diseases, the patient's condition is more complex, requiring more comprehensive disease management.This has made "cardiovascular glucose co-management" becoming one of the key components in improving clinical outcomes. However, the current integration of heart and glucose management still faces many difficulties and challenges:
1.Blood glucose and cardiovascular data were dispersed under the traditional management,
resulting in information gaps for patients after discharge and difficulties in sustained physician intervention.
2.Delayed intervention leads to difficult risk control, and the traditional follow up model cannot optimize blood glucose levels effectively.
3.Management plans are difficult to implement, resulting in poor compliance, while a lack of supervised management reduces effectiveness.
4.High-quality medical resources are concentrated, and primary medical institutions lack mature and scalable management paradigms.
To address these challenges, traditional management models alone are no longer sufficient to meet the needs of diabetes and cardiovascular co-management. Achieving more precise and efficient management requires systematic digital management pathway solutions, which include four stages:
STAGE 1: Through the integration of CGM, smart wearable devices, and cloud-based data, collecting the data and indicators of blood glucose and cardiovascular, breaking down information fragmentation and providing more precise data support for personalized blood glucose management and treatment decision-making.
STAGE 2: Assessing the risk and early warning models by artificial intelligence(AI) to accurately predict abnormal glucose levels and potential cardiovascular events, and proposing personalized intervention plans combined with heart rate and lifestyle.
STAGE 3: Helping patients implement management plans better and improving compliance through lifestyle optimization and online counseling.
STAGE 4: Establishing a closed-loop follow-up and effect tracking mechanism, generating dynamic reports automatically, enables doctors to adjust management strategies continuously, thus achieving controllable, collaborative and efficient health management during the whole process.
Sinocare iCan i6 Pro CGM , Empowering Diabetes Management with Technology
To enhance the interactive experience, Sinocare set up a digital experience zone for "Integrated Management of Heart and Glucose" at the congress venue. Attendees could experience the real-time glucose monitoring capability of the Sinocare iCan i6 Pro CGM ,feeling the convenience and efficiency brought by its advantages:
l Lightweight : All-in-one design, about the size of a 50-cent coin.
l No Finger Pricking Required: Glucose readings are obtained every 3 minutes, with continuous monitoring for 15 days, eliminating the need for finger tip calibration.
l Comprehensive Application(APP) Functions: Converting the dietary carbohydrate automatically , and reminding & recording the insulin medication.
l Online Q&A(Question and Answer): Providing "3v1 + One-stop" glucose control guidance from certified health specialists, dynamically generating and interpreting Ambulatory Glucose Profile (AGP) for free, enabling doctors to implement precise targeted management.
l Hyperglycemia and Hypoglycemia Alerts: Cover 24-hour monitoring gaps,enabling family members to receive real-time glucose notifications , safeguarding parents and children remotely , and alleviating anxiety.
l More Precise: Supported by third-generation glucose sensing technology and six core patents, the system optimizes algorithmic processes across all dimensions.
l More Intelligent: Intelligent recording of dietary glycemic curves and exercise-induced glucose control assessment, supported by carbohydrate counting and insulin dosage calculation tools, enables precise daily blood glucose management.
Through the system demonstration, the audience could not only experience the convenience brought by the Sinocare iCan i6 Pro CGM directly, but also witness how digital management supports the glycemic management of patients with diabetes and cardiovascular diseases, achieving precise, intelligent, and efficient health management.
References:
[1]Goyal A, Mehta SR, Díaz R, et al. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction[J]. Circulation, 2009, 120(24): 2429‑2437. DOI: 10.1161/ CIRCULATIONAHA.108.837765.
[2]Kok MM, von Birgelen C, Sattar N, et al. Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population[J]. EuroIntervention, 2018, 14(9):e1049‑e1056. DOI: 10.4244/EIJ‑D‑17‑01067.
[3] Zhu Y, Hu J, Zhang M, et al. Influence of baseline HbA1c and antiplatelet therapy on 1‑year vein graft outcome[J]. JACC Asia, 2022, 2(2): 197‑206. DOI: 10.1016/j. jacasi.2021.11.009.
[4] Besch G, Pili‑Floury S, Morel C, et al. Impact of post‑procedural glycemic variability on cardiovascularmorbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis[J]. Cardiovasc Diabetol, 2019, 18(1): 27. DOI: 10.1186/s12933‑019‑0831‑3.
[5] Subramaniam B, Lerner A, Novack V, et al. Increased glycemic variability in patients with elevated preoperative HbA1C predicts adverse outcomes following coronary artery bypass grafting surgery[J]. Anesth Analg, 2014, 118(2): 277‑287. DOI: 10.1213/ ANE.0000000000000100.
[6] Li X, Zhou X, Wei J, et al. Effects of glucose variability on short‑term outcomes in non‑diabetic patients after coronary artery bypass grafting: a retrospective observational study[J]. Heart Lung Circ, 2019, 28(10): 1580‑1586. DOI: 10.1016/j.hlc.2018.08.006.
[7] Lin YJ, Lin LY, Peng YC, et al. Association between glucose variability and postoperative delirium in acute aortic dissection patients: an observational study[J]. J Cardiothorac Surg, 2021, 16(1): 82. DOI: 10.1186/ s13019‑021‑01456‑4.
[8] Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation[J]. J Gen Intern Med, 2010, 25(8): 853‑858. DOI: 10.1007/ s11606‑010‑1340‑y.
[9]Esdaile H, Hill N, Mayet J, Oliver N. Glycaemic control in people with diabetes following acute myocardial infarction. Diabetes Res Clin Pract. 2023 May;199:110644. doi: 10.1016/j.diabres.2023.110644. Epub 2023 Mar 29.